Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy

PURPOSE: Allergic rhinoconjunctivitis (ARC) is one of the most common diseases worldwide. Allergen immunotherapy (AIT) is the only causal treatment available so far. Due to health policy provisions, the assessment of treatment benefit from the patient’s perspective is of high relevance. To date, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Langenbruch, Anna, Wüstenberg, Eike, Wolf, Hendrik, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109726/
https://www.ncbi.nlm.nih.gov/pubmed/35586793
http://dx.doi.org/10.2147/JAA.S357469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109726/
https://www.ncbi.nlm.nih.gov/pubmed/35586793
http://dx.doi.org/10.2147/JAA.S357469

Ejemplares similares